Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan: azitrainc.com (AZTR)

The Azitra, Inc. (AZTR) biotech sector is insulated from inflation and GDP fluctuations, demonstrating high resilience to crises. The quarterly EPS history visualizes this stability, where 86.20 shows the current value of the metric. Azitra, Inc. (AZTR) strives for leadership in treating rare skin pathologies, leveraging the synergy between geneticists and microbiologists to create innovative therapies.

Azitra Inc (AZTR) - Wutah bathi EPS kuartalan saka 21.02.2024 nganti 12.11.2026

Ringkesan rincian data analitis Azitra Corporation (AZTR)

- rega saham lan prakiraan rega para ahli:

Rega saham Azitra|AZTR - Target median analis

- indikator kapitalisasi bursa perusahaan:

Nilai pasar Azitra Corp|AZTR - Nilai Bisnis

- data kapitalisasi buku:

Nilai Buku saben Saham Azitra|AZTR - Kapitalisasi Buku|Rasio Kapitalisasi marang Aset Bersih azitrainc.com|AZTR - Nilai Total Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Total Utang marang Modal Azitra, Inc.|AZTR - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Azitra, Inc.|AZTR - Tanggungan utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Azitra Corp|AZTR - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Azitra|Indikator likuiditas cepet azitrainc.com

- indikator bathi lan kelipatan valuasi:

AZTR - Bathi pungkasan|Proyeksi bathi mangsa ngarep Azitra, Inc.|AZTR - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Azitra Corp|AZTR - Rasio P/E diaturake wutah|Pangali EV/EBITDA Azitra Corp|AZTR - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Azitra|AZTR - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan azitrainc.com|AZTR - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Azitra, Inc.

Pambiji fundamental perusahaan:Azitra, Inc.

Investors must eliminate hidden risks by analyzing earnings per share (EPS) trends to assess the actual viability of the business model. By evaluating quarterly EPS progress, one can determine the extent to which modified skin microbe developments are capable of generating value amid market shocks, as this indicator measures net income growth rates, revealing operational efficiency imbalances and confirming the long-term financial stability of Azitra, Inc. (AZTR).

Karo sapa Azitra, Inc. saingan